Key facts

Active Substance
  • birch pollen
  • alder pollen
  • hazel pollen
Therapeutic area
Pneumology-allergology
Decision number
P/329/2010
PIP number
EMEA-000958-PIP01-10
Pharmaceutical form(s)
Oral solution
Condition(s) / indication(s)
Treatment of allergic rhinitis / rhino-conjunctivitis
Route(s) of administration
Sublingual use
Contact for public enquiries

ROXALL Medizin GmbH

info@roxall.deGermany
Phone: +49 408972520
Fax: +49 4089725223

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date

Decision

Share this page